ea0092ps3-24-05 | Thyroid Eye Disease | ETA2023
Men Clara
, Amarikwa Linus
, Sears Connie
, Shinder Roman
, Clauss Kevin
, Ugradar Shoaib
, Cockerham Kimberly
, Wester Sara
, Douglas Raymond
, Kossler Andrea
Introduction: The initial clinical trials for teprotumumab excluded patients with previous orbital irradiation, surgery, glucocorticoid use (cumulative dose > 1gm), or biologic treatment. Therefore, information on the use of teprotumumab for patients who failed prior therapy is limited. Our purpose is to characterize the efficacy of teprotumumab for the treatment of recalcitrant TED.Methods: This is a multicenter retrospective study of all patients t...